Thomas Strecker

TL;DR: RVSV-ZEBOV was reactogenic but immunogenic after a single dose and warrants further evaluation for safety and efficacy, and glycoprotein-binding antibody titers were sustained through 180 days in all participants.

TL;DR: The chimpanzee adenovirus 3 (ChAd3) vaccine boosted with MVA elicited B-cell and T-cell immune responses to ZEBOV that were superior to those induced by the ChAd3 vaccine alone.

TL;DR: Deep sequencing of 179 patient samples processed by the European Mobile Laboratory, the first diagnostics unit to be deployed to the epicentre of the outbreak in Guinea, reveals an epidemiological and evolutionary history of the epidemic from March 2014 to January 2015, providing an unprecedented window into the evolution of an ongoing viral haemorrhagic fever outbreak.

TL;DR: It is demonstrated that the Lassa virus Z protein is abundant in viral particles, is strongly membrane associated, is sufficient in the absence of all other viral proteins to release enveloped particles, and contains two late domains necessary for the release of virus-like particles.

TL;DR: A synthetic approach that very rapidly generated vaccine viruses from sequence data was developed, which could shave weeks off the time needed for vaccine manufacture and put us in a much better position to respond quickly to a sudden pandemic.